Published in Hepatology on May 14, 2014
The global burden of liver disease: the major impact of China. Hepatology (2014) 4.23
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One (2015) 1.51
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. Am J Transplant (2015) 1.44
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology (2015) 1.28
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology (2015) 1.10
Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol (2015) 0.88
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology (2014) 0.85
Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol (2015) 0.83
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat (2014) 0.82
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach. BMC Infect Dis (2015) 0.79
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clin Mol Hepatol (2015) 0.79
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther (2016) 0.79
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol (2016) 0.78
The good, the bad and the ugly of the new treatments for hepatitis C virus. Ann Hepatol (2014) 0.77
Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol (2014) 0.77
Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther (2016) 0.76
Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol (2016) 0.76
From HCV To HBV Cure. Liver Int (2017) 0.75
Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors. Antivir Ther (2015) 0.75
Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation (2016) 0.75
Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands. PLoS One (2016) 0.75
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One (2016) 0.75
Total joint arthroplasty in patients with chronic infectious liver disease. Arthroplast Today (2015) 0.75
A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Iran Red Crescent Med J (2016) 0.75
Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China. Medicine (Baltimore) (2017) 0.75
Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One (2017) 0.75
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ (2016) 0.75
Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties. Bioorg Med Chem Lett (2017) 0.75
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 9.35
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med (2008) 3.54
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis (2012) 2.19
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology (1999) 1.90
Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis (2011) 1.81
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl (2010) 1.69
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int (2014) 1.62
All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis (2011) 1.60
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother (2010) 1.42
Health-state utilities in liver disease: a systematic review. Med Decis Making (2008) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol (2002) 1.27
Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol (2009) 1.25
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23
Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol (2012) 1.22
Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl (2002) 1.22
Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology (1994) 1.14
Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer (2008) 1.11
Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl (2010) 1.08
Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol (2005) 1.08
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother (2013) 1.04
Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol (2004) 1.00
The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int (2009) 0.93
Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol (2012) 0.83
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology (2010) 2.53
Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37
Needlestick injuries among surgeons in training. N Engl J Med (2007) 2.37
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials (2008) 2.01
Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother (2003) 1.99
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother (2005) 1.83
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol (2003) 1.83
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge. J Nat Prod (2003) 1.81
Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues. Antimicrob Agents Chemother (2002) 1.79
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J Biol Chem (2010) 1.70
Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther (2012) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry. Chem Rev (2009) 1.53
Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem (2005) 1.51
Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother (2006) 1.49
Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol (2003) 1.39
Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases. J Nat Prod (2004) 1.36
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology (2010) 1.35
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry (2003) 1.32
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS (2008) 1.32
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology (2012) 1.31
The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem (2005) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother (2006) 1.28
Racial differences in hepatitis C treatment eligibility. Hepatology (2011) 1.28
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother (2009) 1.27
Manadomanzamines A and B: a novel alkaloid ring system with potent activity against mycobacteria and HIV-1. J Am Chem Soc (2003) 1.27
Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One (2010) 1.27
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology (2012) 1.19
5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemother Pharmacol (2005) 1.17
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology (2005) 1.17
Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem (2006) 1.16
Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2005) 1.16
Best strategies for global HCV eradication. Liver Int (2013) 1.16
Treatment of chronic hepatitis C: a systematic review. Hepatology (2002) 1.14
Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol (2013) 1.14
Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev (2014) 1.13
The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr (2003) 1.13
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem (2004) 1.12
Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr (2003) 1.11
Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects. HIV Clin Trials (2011) 1.10
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother (2013) 1.08
Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology (2014) 1.08
Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem (2007) 1.07
Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med (2014) 1.04
Food insufficiency and medication adherence among people living with HIV/AIDS in urban and peri-urban settings. Prev Sci (2011) 1.03
Simian immunodeficiency virus macaque models of HIV latency. Curr Opin HIV AIDS (2011) 1.03
Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 1.02
Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J Biol Chem (2013) 1.02
Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry. Anal Chem (2010) 1.01
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS (2009) 1.00
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut (2011) 1.00
In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrob Agents Chemother (2005) 0.99
Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem (2008) 0.99
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology (2014) 0.98
Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose. Antivir Ther (2004) 0.98
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemother (2003) 0.98
Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther (2010) 0.98
Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. J Biol Chem (2009) 0.98
Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. Antivir Chem Chemother (2003) 0.98
Antiretroviral-associated liver injury. Clin Liver Dis (2003) 0.97
Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett (2005) 0.97
Abundant non-canonical dUTP found in primary human macrophages drives its frequent incorporation by HIV-1 reverse transcriptase. J Biol Chem (2011) 0.95
Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol (2010) 0.95
Randomized clinical trial of HIV treatment adherence counseling interventions for people living with HIV and limited health literacy. J Acquir Immune Defic Syndr (2013) 0.95
Anti-infective discorhabdins from a deep-water alaskan sponge of the genus Latrunculia. J Nat Prod (2010) 0.95
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother (2014) 0.94
Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry (2002) 0.94
Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS. Ann Behav Med (2011) 0.93
Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis (2005) 0.93
Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activity. Bioorg Med Chem (2006) 0.93
The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. Mol Biol Int (2012) 0.93
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther (2006) 0.93
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis (2012) 0.93
Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother (2008) 0.92
Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs. Antivir Chem Chemother (2009) 0.92
dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages. Retrovirology (2014) 0.92